Clinical outcomes in cancer patients with concurrent venous thromboembolism: findings from the RIETE registry

Published: June 3, 2009
Abstract Views: 195
PDF: 492
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

n cancer patients who develop venous thromboembolism (VTE) the risk of death is more than threefold higher than in patients without cancer who have VTE1-3 and in those with cancer but no VTE.4 The high mortality rate in cancer patients with VTE is probably due to both the VTE and the fact that malignancies associated with VTE appear to follow a more aggressive course. Identifying clinical characteristics that put cancer patients with VTE at increased risk of death, either due to PE or bleeding complications, is important if their outcomes are to be improved.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Monreal, M., Falgá, C., Vilaseca, B., Suárez, C., Gabriel, F., Carles Tolosa, C., & Montes, J. (2009). Clinical outcomes in cancer patients with concurrent venous thromboembolism: findings from the RIETE registry. Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.334